Investor Relations

Partnerships are integral to Harbour BioMed's strategy to build a fully integrated biopharmaceutical company.

  1. Apr 09, 2022

    HBM7022 Out-license to AstraZeneca

  2. Mar 25, 2022

    2021 Annual Results Online Conference

  3. Dec 08, 2021

    201 R&D Day

  4. Sep 14, 2021

    HBM4003 Phase I Data Readout

  5. Aug 31, 2021

    2021 Interim Results Conference Call